Clinical use of lopinavir/ritonavir in a salvage therapy setting: Pharmacokinetics and pharmacodynamics

AIDS

Volumn 16, Issue 15, 2002, Pages 2081-2083

  Boffito, Marta ^a   Arnaudo, Isabella ^a   Raiteri, Riccardo ^a   Bonora, Stefano ^a   Sinicco, Alessandro ^a   Di Garbo, Antonio ^a   Reynolds, Helen E ^a   Hoggard, Patrick G ^a   Back, David J ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR;

ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SALVAGE THERAPY; VIRUS LOAD; VIRUS MUTATION;

CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; PYRIMIDINONES; RITONAVIR; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037131327     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200210180-00015     Document Type: Article

References (8)

1. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001, 15:F1-F9.
2. Kempf D, Hsu A, Isaacson P, et al. Evaluation of the inhibitory quotient as a pharmacodynamic predictor of the virologic response to protease inhibitor therapy. In: 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, April 2001 [Abstract 7.3].
3. 50 relationship as a predictor of viral response for ABT-378/ritonavir (ABT-378/r) in treatment-experienced patients. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [Abstract 171].
4. Cohen Codar I, Boer F, Terrier R, et al. Pre-registrational use of ABT378/r in heavily-experienced patients: the french ATU program experience. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 2001 [Abstract 1926].
5. Kempf D, King M, Isaacson J, Rode R, Brun S, Sun E. Analysis of mutational patterns associated with response to lopinavir/ritonavir in multiple protease inhibitor-experienced patients. In: 5th International Workshop on HIV Drug Resistance and Treatment Strategies. Scottsdale, June 2001 [Abstract 61].
6. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor experienced patients. J Virol 2001, 75:7462-7469.
7. Reynolds HE, Tjia JF, Gibbons SE, Khoo SH, Back DJ. Simultaneous determination of four HIV protease inhibitors by HPLC-MS/MS for use in a therapeutic drug monitoring service. Br J Clin Pharmacol 2001, 52:481P.
8. Dawson-Saunders B, Trapp RG. Evaluating diagnostic procedures. In: Basic and clinical biostatistics. East Norwalk, Appleton and Lange; 1990. pp. 240-242.